BioSpace News Archive

Business

Autolus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 10

Autolus Therapeutics plc today announced that it will release its fourth quarter and full year 2021 financial results and operational highlights before open of U.S. markets on Thursday, March 10, 2022.

February 21, 2022

·

1 min read

Business

ReWalk Robotics to Report Fourth Quarter 2021 Financial Results on February 24, 2022

ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will release its fourth quarter 2021 financial results on Thursday, February 24, 2022, before the U.S. financial markets open.

February 21, 2022

·

1 min read

Business

ELNA Medical Passes a New Tech Milestone with Appointment of First Chief AI Officer

Montreal -based ELNA Medical announced today the appointment of Dr. Maxime Cohen as its first Chief Artificial Intelligence Officer (CAIO).

February 21, 2022

·

2 min read

FDA

U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for KEYTRUDA® (pembrolizumab) to Identify Patients with Microsatellite Instability-High (MSI-H) Solid Tumors

Foundation Medicine’s tissue-based comprehensive genomic profiling test is now the first and only FDA-approved companion diagnostic to aid in identifying patients with MSI-H solid tumors who may benefit from immunotherapy.

February 21, 2022

·

4 min read

Bio NC

Calyx EDC Selected for RWE Data Collection in Lengthy, Late Phase Trial

Calyx today announced its electronic data capture (EDC) system has been selected by a leading pharmaceutical company to capture Real World Evidence (RWE) data for a global, late phase study.

February 21, 2022

·

1 min read

Business

Harbour BioMed Announces IND Approval for Next-Gen Anti-TSLP Fully Human Monoclonal Antibody

Harbour BioMed (“HBM”, HKEX: 02142) announced that China National Medical Products Administration (NMPA) had approved its investigational new drug (IND) application for HBM9378 (or SKB378 as referred to by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

February 21, 2022

·

4 min read

Drug Development

NovelMed Announces Interim Positive Results from Its Phase I Clinical Trial of NM8074, a Bb Complement Alternative Pathway Blocker Antibody

NovelMed Therapeutics, Inc. announced today interim positive results from a First-in-Human Phase I clinical trial of its complement blocker monoclonal anti-Bb antibody, known as NM8074.

February 21, 2022

·

5 min read

Drug Development

Adlai Nortye Announces Publication of Preclinical Research of AN3025 (anti-hTNFR2）in Frontiers in Immunology

Adlai Nortye Ltd. announced the publication of preclinical research of AN3025 (anti-hTNFR2）in the peer-reviewed journal Frontiers in Immunology.

February 21, 2022

·

4 min read

BioMidwest

Functional Fluidics’ Red Blood Cell Biomarkers May Prove to be Effective Surrogate Endpoints for Sickle Cell Disease Severity

Functional Fluidics (https://www.functionalfluidics.com/) officially announced the publication of its two-year study, demonstrating that its red blood cell (RBC) health biomarkers can identify individuals with sickle cell disease at greatest risk for more severe outcomes.

February 21, 2022

·

3 min read

Business

Daewoong Pharmaceutical Posts Record Annual Revenue in 2021, with Export Growth of Nabota and New Drug Development

Daewoong Pharmaceutical (Daewoong) (CEO Sengho Jeon & Changjae Lee) recently announced its 2021 financial results with its all-time high revenue.

February 21, 2022

·

4 min read